SEC Form 4 · accession 0001144204-18-002949
Eloxx Pharmaceuticals, Inc. · ELOX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Pedro Huertas
Officer — Chief Medical Officer
Period of report
Jan 15, 2018
Accepted (ET)
Jan 22, 2018 · 9:25 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001035354
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $6.65 | Jan 15, 2018 | A | 50,000 | A | — | Jan 15, 2028 | Common Stock | 50,000 | 50,000 | D |
Explanation of responses
- F1The option vests over a four-year period commencing on January 15, 2018 in sixteen equal quarterly installments.